Source: MHRA / Gov.uk 13.6.22
Bristol Laboratories Limited are recalling a batch of this product as a precautionary measure due to low dissolution test results reported during ongoing stability studies.
Bristol Laboratories Limited
Phenobarbital 60 mg Tablets
|Batch number||Expiry date||Pack size||First distributed|
|NW0001||December 2022||28||30 September 2020|
Active Pharmaceutical Ingredient: Phenobarbital
Brief description of the problem
Bristol Laboratories Limited are recalling the above batch of product as a precautionary measure due to low dissolution test results reported during ongoing stability studies.
Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
Advice for patients
- This is a precautionary Pharmacy and Wholesaler level recall, therefore no further action is required by patients.
- Patients should continue taking medicines from this batch, as stopping phenobarbital treatment abruptly is likely to cause harm.
- Never stop taking medicines such as phenobarbital without medical advice. Suddenly stopping an epilepsy medicine may cause your seizures to start again or happen more often or last longer than before.
- The Marketing Authorisation Holder have not received any reports of adverse reactions related to the issue above, however, patients who experience a change of their condition or symptoms or any adverse reactions should seek medical attention. These should also be reported via the MHRA Yellow Card scheme.
For more information, medical or supply enquiries, please contact firstname.lastname@example.org.
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Defective Medicines Report Centre
10 South Colonnade
Telephone +44 (0)20 3080 6574
Click here for the source.